| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Prev Med Public Health > Volume 41(2); 2008 > Article
Journal of Preventive Medicine and Public Health 2008;41(2): 74-79. doi: https://doi.org/10.3961/jpmph.2008.41.2.74
Current State and Challenges of Pharmacoeconomic Evaluation in Korea.
Sang Eun Choi
Seoul National University, College of Pharmacy, Seoul, Korea. truse00@snu.ac.kr
ABSTRACT
Since the positive listing system for prescription drug reimbursement has been introduced in Korea, the number of pharmacoeconomic evaluation studies has increased. However it is not clear if the quality of pharmacoeconomic evaluation study has improved. Due to the lack of randomized clinical studies in Korean health care setting, Korean economic evaluation studies have typically integrated the local cost data and foreign clinical data. Therefore methodological issues can be raised in regard to data coherence and consistency. But the quality of data was not questiened and the potential bias has not been investigated yet. Even though changes in policy have encouraged the undertaking of pharmacoeconomic evaluations, there is few public-side funding for validation study of cost-effectiveness models and data. Several companies perform economic evaluation studies to be submitted on behalf of their own products, but do not want the study results to be disclosed to the academic community or public. To improve the present conduct of pharmacoeconomic evaluations in Korea, various funding sources need to be developed, and, like other multidisciplinary areas, the experts in different fields of study should collaborate to ensure the validity and credibility of pharmacoeconomic evaluations.
Key words: Pharmacoeconomic evaluation; Validation; Cost-effectiveness model; Research funding
Editorial Office
#203, 92 Wangsan-ro, Dongdaemun-gu, Seoul 02585, Korea
Tel : +82-2-740-8328   Fax : +82-2-764-8328   E-mail: jpmph@prevmed.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © 2023 by Korean Society for Preventive Medicine.                 Developed in M2PI